ELV analyst estimates
Elevance Health (ELV) analyst ratings, the average price target and its range, and every firm's latest call.
ELV analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 23, 2026 | Goldman Sachs | Elevance Health price target raised to $451 from $395 at Goldman Sachs | $451.00 |
| Oct 23, 2026 | Mizuho Securities | Elevance Health price target raised to $490 from $470 at Mizuho | $490.00 |
| Oct 23, 2026 | Piper Sandler | Elevance (ELV) PT Raised to $520 at Bernstein SocGen Group | $520.00 |
| Oct 22, 2026 | Barclays | Elevance Health price target raised to $472 from $469 at Barclays | $472.00 |
| Oct 22, 2026 | Robert W. Baird | Elevance Health price target raised to $406 from $393 at Baird | $406.00 |
| Oct 22, 2026 | Guggenheim | Elevance Health price target raised to $485 from $460 at Guggenheim | $485.00 |
| Oct 22, 2026 | RBC Capital | Elevance Health price target raised to $455 from $424 at RBC Capital | $455.00 |
| Oct 22, 2026 | UBS | Elevance Health price target raised to $523 from $460 at UBS | $523.00 |
| Oct 12, 2026 | Guggenheim | Elevance (ELV) PT Raised to $460 at Guggenheim | $460.00 |
| Oct 7, 2026 | Barclays | Elevance Health price target raised to $469 from $457 at Barclays | $469.00 |
| Jul 17, 2026 | Leerink Partners | Elevance Health price target raised to $395 from $364 at Leerink | $395.00 |
| Jul 16, 2026 | Goldman Sachs | Elevance Health price target raised to $395 from $370 at Goldman Sachs | $395.00 |
| Jul 16, 2026 | RBC Capital | Elevance Health price target lowered to $424 from $439 at RBC Capital | $424.00 |
| Jul 16, 2026 | New Street | Bernstein SocGen on Elevance (ELV): 'ELV announces market exits in Medicaid' | $482.00 |
| Jul 16, 2026 | Bernstein | Elevance Health price target raised to $488 from $482 at Bernstein | $488.00 |
- 19 firms rate ELV: 14 buy, 5 hold, 0 sell.
- The average price target is $469.73 from 11 analysts, from $395.00 to $523.00.
Updated 2026-11-07 11:52 UTC